The Week in Review: DSM and Sinochem Launch Antibiotic JV
Royal DSM and Sinochem won regulatory approval to launch their JV, which calls for Sinochem to pay $291 million for 50% stake in DSM’s anti-infectives unit; Nycomed’s acquisition of Guangdong Techpool Biopharma and a direct sales model in China boosted Nycomed’s Q2 revenues; Merck Serono opened a China lab as part of its planned R&D hub in Beijing; SinoCubate launched as an incubator/investor in mainland China companies; and NexBio released positive data from a Phase II trial of a novel biologic that aims to both treat and prevent infection by all flu strains. More details…. Stock Symbols: (XAMS: DSM) (Xetra: MRK) (OTCBB: SBAT) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here